REG - MD Medical Group - Endovascular heart surgery on a newborn at MDMG

MD Medical InvestmentsAnnouncement

17/08/2021 09:00

RNS Number : 8809I
  
MD Medical Group Investments PLC
  
17 August 2021
  
 

First in Russia endovascular heart surgery on a newborn performed at MDMG
 
17 August 2021, Moscow - MD Medical Group Investments Plc ("MD Medical Group", "MDMG" or the "Company" - LSE: MDMG), a leading Russian private healthcare provider, today announces that for the first time in Russia and in the practice of the MD Group Clinical hospital an endovascular heart surgery was performed on a premature newborn with low birth weight.
 
The MD Group Clinical hospital's specialists successfully performed an operation to close the arterial duct of a newborn (30 weeks gestation) with a weight of 880 grams on the 13th day after birth. The infant's weight was 1050 grams on the day of surgery.
 
The unique feature of the surgery is that it was performed without incisions by puncturing a vessel in the thigh area of the newborn who was implanted with a special occluder (device for closing the duct), measuring 4.0 mm.
 
In the past, for infants with this pathology, the duct was closed either using special drugs that have certain counterindications, or surgically during an open operation. This time, doctors decided not to use drug therapy due to its counterindications.
 
Mark Kurtser, CEO of MD Medical Group, said: 
 
"The unique operation performed by our doctors demonstrates MDMG's strong competencies in two spheres - in perinatal medicine, in which we have been specialising for many years, and in a relatively new field for us - endovascular surgery. This succesful operation will also further enlarge our possibilities in the sphere of pediatrics. Today, all our hospitals are being developed as major multifunctional centers and we will continue to introduce advanced techniques for the treatment of patients of all ages in various medical areas".
 
For further information please contact:



Investors


Media




            
Dmitry Yakushkin 
MD Medical Group Investments Plc
Tel: +7 495 139 8740 ext. 16329

d.yakushkin@mcclinics.ru


EM

Tom Blackwell: +7 919 102 9064
Sergii Pershyn: +1 929 855 8188
MDMG@em-comms.com



About MD Medical Group
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 42 modern healthcare facilities, including 6 hospitals and 36 out-patient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, Volgograd, Tula, Kazan, Vladivostok, Krasnodar and Rostov-on-Don.
The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
Since November 9, 2020 the Company's GDRs are traded also on the Moscow Exchange. Quotation is done in Russian Rubles.
Forward-Looking Statements:
This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCSFMSWWEFSEDA